Literature DB >> 17239011

Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis.

S Leech1, J Kirk, J Plumb, S McQuaid.   

Abstract

Epithelial and endothelial tight junctions are pathologically altered in infectious, inflammatory, neoplastic and other diseases. Previously, we described such abnormalities, associated with serum protein leak, in tight junctions of the blood-brain barrier endothelium, in lesional and normal-appearing white matter (NAWM) in secondary progressive (SP) and acute multiple sclerosis (MS). This work is extended here to lesions and NAWM in primary progressive multiple sclerosis (PPMS) and to cortical grey matter in PPMS and SPMS. Immunocytochemistry and semiquantitative confocal microscopy for the tight junction protein zonula occludens 1 (ZO-1) was performed on snap-frozen sections from PPMS (n = 6) and controls (n = 5). Data on 2103 blood vessels were acquired from active lesions (n = 10), inactive lesions (n = 15), NAWM (n = 42) and controls (n = 20). Data on 1218 vessels were acquired from normal-appearing grey matter (PPMS, 5; SPMS, 6; controls, 5). In PPMS abnormal ZO-1 expression in active white matter lesions and NAWM, was found in 42% and 13% of blood vessels, respectively, comparable to previous data from acute and SPMS. In chronic white matter plaques, however, abnormalities were considerably more frequent (37%) in PPMS than in SPMS. Abnormality was also more frequent in normal-appearing grey matter in SPMS (23%) than in PPMS (10%). In summary, abnormal tight junctions in both SPMS and PPMS are most frequent in active white matter lesions but persist in inactive lesions, particularly in PPMS. Abnormal tight junctions are also common in normal-appearing grey matter in SPMS. Persistent endothelial abnormality with leak (PEAL) is therefore widespread but variably expressed in MS and may contribute to disease progression.

Entities:  

Mesh:

Year:  2007        PMID: 17239011     DOI: 10.1111/j.1365-2990.2006.00781.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  35 in total

1.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

2.  Bovine serum albumin promotes IL-1beta and TNF-alpha secretion by N9 microglial cells.

Authors:  Tian-zhi Zhao; Yong-zhi Xia; Lan Li; Jian Li; Gang Zhu; Shi Chen; Hua Feng; Jiang-kai Lin
Journal:  Neurol Sci       Date:  2009-08-21       Impact factor: 3.307

3.  IFN-γ promotes transendothelial migration of CD4+ T cells across the blood-brain barrier.

Authors:  Sandip Ashok Sonar; Shagufta Shaikh; Nupura Joshi; Ashwini N Atre; Girdhari Lal
Journal:  Immunol Cell Biol       Date:  2017-07-06       Impact factor: 5.126

Review 4.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

5.  Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.

Authors:  Friederike Pfeiffer; Julia Schäfer; Ruth Lyck; Victoria Makrides; Sarah Brunner; Nicole Schaeren-Wiemers; Urban Deutsch; Britta Engelhardt
Journal:  Acta Neuropathol       Date:  2011-10-09       Impact factor: 17.088

6.  Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.

Authors:  François Curtin; Virginie Vidal; Corinne Bernard; Arno Kromminga; Alois B Lang; Hervé Porchet
Journal:  MAbs       Date:  2016-03-30       Impact factor: 5.857

7.  [Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients].

Authors:  E Mauch; J Zwanzger; R Hettich; C Fassbender; R Klingel; F Heigl
Journal:  Nervenarzt       Date:  2011-12       Impact factor: 1.214

8.  High-mobility group box 1 in multiple sclerosis.

Authors:  Zohara Sternberg; Daniel Sternberg; Trevor Chichelli; Allison Drake; Neel Patel; Chana Kolb; Kailash Chadha; Jinhee Yu; David Hojnacki
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

9.  Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination.

Authors:  Nathanael J Lee; Seung-Kwon Ha; Pascal Sati; Martina Absinta; Nicholas J Luciano; Jennifer A Lefeuvre; Matthew K Schindler; Emily C Leibovitch; Jae Kyu Ryu; Mark A Petersen; Afonso C Silva; Steven Jacobson; Katerina Akassoglou; Daniel S Reich
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

Review 10.  Relapsing and progressive forms of multiple sclerosis: insights from pathology.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.